The news for Multiple Sclerosis patients just keeps getting better and better. Another pharmaceutical company has joined the race to be first-to-market with a new oral medication for the treatment of Multiple Sclerosis. 
Novartis AG is expected to apply for approval for it’s oral medication FTY720 (Fingolimod) before the end of the year. Read the full results of the TRANSFORM Trial! http://www.empowher.com/news/herarticle/2009/08/10/fty720-fingolimod-oral-medication-multiple-sclerosis%E2%80%93results-transform-tr
Tags: Cladribine, CLARITY trial, empowher, empowher.com, FTY720 (Fingolimod), Multiple Sclerosis, oral medication for multiple sclerosis, oral medication for treatment of Multiple Sclerosis, Transform Trial